Chicago, United States
ClostraBio, Inc, founded in 2016 and headquartered in the United States, is at the forefront of biopharma and biotechnology innovation. The company is committed to developing cutting-edge dietary supplements and therapeutics targeting gut health, particularly inflammatory bowel disease (IBD) and food allergy.
Their flagship product, CLB101™, is a pioneering strain of Anaerostipes caccae, introduced in 2025, that signifies a breakthrough in gut health solutions. Unlike traditional probiotics, CLB101™ ensures continuous, localized butyrate production within the lower gut, thereby addressing common shortcomings of existing supplements which often fail to deliver butyrate effectively.
In terms of financial traction, ClostraBio secured a $4.00M Series A investment from Portal Innovation Ventures as of September 2022. This investment underscores confidence in the company's potential to reshape gut health strategies with innovative solutions.
